What is INTS stock price today?

INTS (Intensity Therapeutics Inc) stock is trading at $5.50 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is INTS stock going up or down today?

INTS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy INTS stock now?

The decision to buy INTS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is INTS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for INTS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is INTS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if INTS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is INTS's P/E ratio?

P/E ratio data for INTS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is INTS's market cap?

INTS (Intensity Therapeutics Inc) has a market capitalization of $0.01 billion, making it a small-cap stock.

What is INTS's price to book ratio?

INTS trades at a price-to-book (P/B) ratio of 1.18, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does INTS pay dividends?

INTS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is INTS's dividend yield?

INTS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is INTS stock a good long-term investment?

INTS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is INTS's revenue growth rate?

Revenue growth data for INTS is available on our dashboard with detailed financial statement analysis.

Profitability metrics for INTS are available on our dashboard with complete income statement analysis.

What are the risks of investing in INTS?

Key risks for INTS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does INTS compare to its competitors?

Compare INTS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize INTS's performance and positioning.

What is INTS's stock price target for 2026?

Our AI model provides price targets for INTS based on fundamental analysis: Bull case $7.15 (+30%), Base case $6.32 (+15%), Bear case $4.95 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about INTS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for INTS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is INTS's next earnings report?

INTS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

INTS - Intensity Therapeutics Inc

NYSE * Health Care * Biotechnology

$5.50

$-0.10 (-1.79%)

About Intensity Therapeutics Inc

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

INTS Key Statistics

Market Cap

$13.97M

P/B Ratio

1.18

EPS

$-8.56

Employees

How INTS Compares to Peers

INTS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
INTS(This stock)	$13.97M	N/A	0%	0.0%	-
AMGNAmgen Inc	$189.22B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$172.51B	20.5	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.97B	28.5	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.17B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.38B	19.7	-0%	0.1%	vs BIIB

Intensity Therapeutics Inc Company Information

Headquarters: Connecticut; U.S.A
Website: www.intensitytherapeutics.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 14, 2026 at 5:36 PM EDT

Ready to invest in INTS?

Commission-free trading available. Affiliate links.

INTS Lician Score

5% confidence

4.0/10

Neutral

INTS has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates INTSacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

INTS Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for INTS

Dashboard

Enter a ticker to analyze